Core Viewpoint - The company Yirui Technology (688301) announced a capital increase and share expansion for its wholly-owned subsidiary Yirui Imaging Technology (Hefei) Co., Ltd., introducing strategic investor Hefei Jianrui No. 1 Equity Investment Fund Partnership (Limited Partnership) [1] Group 1 - The Jianrui No. 1 Fund plans to invest 500 million yuan in cash to subscribe for the newly increased registered capital of Yirui Hefei [1] - After the capital increase, the Jianrui No. 1 Fund will hold 22.12% of Yirui Hefei's shares, while the company will retain 77.88%, keeping Yirui Hefei as a controlled subsidiary within the company's consolidated financial statements [1] - The introduction of a local state-owned investor through this capital increase is expected to deepen strategic cooperation among parties and accelerate the implementation of the silicon-based OLED micro-display module backplane project [1]

中国国际金融股份有限公司 关于奕瑞电子科技集团股份有限公司 部分募投项目实施主体由全资子公司变更为控股子公司的核查意 见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为奕瑞电子科 技集团股份有限公司（以下简称"奕瑞科技"或"公司"）的保荐机构，根据《证券发行上 市保荐业务管理办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上 市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关 法律、行政法规、部门规章及业务规则的要求，对奕瑞电子科技集团股份有限公司部分 募投项目实施主体由全资子公司变更为控股子公司的事项进行了认真、审慎核查，具体 情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海奕瑞光电子科技股份有限公司向不特 定对象发行可转债注册的批复》（证监许可[2022]2167 号）同意注册，公司向不特定 对象共计发行 14,350,100 张可转换公司债券，每张面值为人民币 100 元，按面值发 行。本次发行可转债募集资金总额为人民币 143,501.00 万元；扣除发行费用（不含增 值税）人民币 1,369.65 万元后，募集资金 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-112 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于全资子公司增资扩股引入战略投资人 暨放弃优先认购权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 奕瑞电子科技集团股份有限公司（以下简称"公司"）全资子公司奕瑞影 像科技（合肥）有限公司（以下简称"奕瑞合肥"或"标的公司"）拟实施增资扩 股并引入战略投资人合肥建瑞壹号股权投资基金合伙企业（有限合伙）（以下简 称"建瑞壹号基金"）。建瑞壹号基金拟现金出资 50,000.00 万元认购奕瑞合肥新 增注册资本 45,454.55 万元（以下简称"本次增资"或"本次交易"），其余 4,545.45 万元计入奕瑞合肥资本公积，公司就本次增资事项放弃优先认购权。 本次增资完成后，奕瑞合肥的注册资本将由 160,000.00 万元增加至 205,454.55 万元。建瑞壹号基金将持有奕瑞合肥 2 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-113 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于公司部分募投项目实施主体由全资子公司变更 为控股子公司的公告 本公司董事会、全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奕瑞电子科技集团股份有限公司（以下简称"公司"）于 2025 年 12 月 25 日 召开第三届董事会第二十三次会议，审议通过《关于公司部分募投项目实施主体 由全资子公司变更为控股子公司的议案》，由于公司全资子公司奕瑞影像科技（合 肥）有限公司（以下简称"奕瑞合肥"）拟实施增资扩股并引入战略投资人，因此 奕瑞合肥将由公司全资子公司变更为公司控股子公司。鉴于奕瑞合肥为公司部分 募投项目实施主体，公司召开董事会，同意将涉及的部分募投项目实施主体由公 司全资子公司变更为公司控股子公司；同意公司在本次引入战略投资人后，通过 委托贷款方式将募集资金投入到奕瑞合肥，并授权公司管理层全权负责上述提供 委托贷款事 ...

Group 1 - The core announcement is about the capital increase and share expansion of Yirui Hefei, a wholly-owned subsidiary of Yirui Technology, which will introduce strategic investor Jianrui No. 1 Fund [1] - Jianrui No. 1 Fund plans to invest 500 million yuan in cash to subscribe for an additional registered capital of 455 million yuan, with the remaining 45.45 million yuan allocated to the capital reserve of Yirui Hefei [1] - After the capital increase, the registered capital of Yirui Hefei will rise from 1.6 billion yuan to 2.055 billion yuan, with Jianrui No. 1 Fund holding 22.12% of the shares and Yirui Technology retaining 77.88% [1] Group 2 - The capital increase will not constitute a related party transaction or a major asset restructuring, and it has been approved by the board of directors [1] - The funds raised from this capital increase will be used for the silicon-based OLED micro-display backplane project, which has a total investment not exceeding 1.8 billion yuan [1]

Group 1 - The core point of the article is the resignation of Qiu Min as the Secretary of the Board of Yirui Technology due to personal reasons, with Bian Ren appointed as the new Secretary [2] - Qiu Min's term was originally set to expire on November 23, 2026, and after his resignation, he will no longer hold any position within the company [2] - Bian Ren, born in 1992 and holding a master's degree, has a background in investment banking and previously worked on Yirui Technology's IPO project [5] Group 2 - Yirui Technology's stock has seen a significant decline, with the number of shares held by funds dropping by 64.39% from the second quarter to the third quarter of 2025, reducing the holding ratio from 21.12% to 7.52% [5] - As of December 19, Yirui Technology's market capitalization is 22.5 billion yuan, which represents a loss of nearly 20 billion yuan from its historical peak since its IPO [5] - The stock price experienced a maximum decline of 21.67% in the fourth quarter [5]

Group 1 - The core viewpoint of the articles highlights a significant upward movement in the medical device sector, driven by policy changes and market dynamics, with a particular focus on the launch of the sixth batch of high-value medical consumables procurement [1][2] - The medical device index ETF (159898) saw a 1.29% increase, with substantial purchases of 36 million units during trading, indicating strong investor interest [1] - Key stocks within the sector, such as SINO Medical and Mailland, experienced notable gains, with increases exceeding 14% and 11% respectively, reflecting positive market sentiment [1] Group 2 - The sixth batch of national high-value medical consumables procurement is set to begin on January 13, 2026, introducing new mechanisms to prevent malicious low pricing, including the concept of anchor pricing and a multi-revival mechanism [1] - The National Medical Products Administration has released new regulations to support medical device exports, which will take effect on May 1, 2026, aimed at optimizing the process for obtaining export sales certificates [1] - Northeast Securities predicts that 2026 will be a year of value reconstruction for the Chinese medical device sector, driven by improved cash flow in hospitals and expectations of policy optimization [2]

Core Viewpoint - The medical device sector is experiencing a positive shift, driven by new policies and market dynamics, with significant investment opportunities emerging as institutional holdings remain low [3][4]. Group 1: Market Performance - On December 25, major indices rose collectively, with the medical device index ETF (159898) increasing by 1.47%, attracting over 18 million yuan in net inflows during the session [1]. - Key stocks in the sector saw substantial gains, including Sino Medical up over 14%, and other notable increases from MaiLand and Weisi Medical [1]. Group 2: Policy Developments - A new round of national procurement for high-value medical consumables has been initiated, set to open bidding on January 13, 2026, focusing on drug-coated balloons and urological intervention consumables [2][3]. - The introduction of anchor pricing and a multi-revival mechanism in the sixth batch of procurement aims to balance price reductions and prevent malicious underpricing [3]. Group 3: Industry Outlook - The release of the "Regulations on the Management of Export Sales Certificates for Medical Devices" on December 25 is expected to support medical device exports, with implementation starting on May 1, 2026 [3]. - Northeast Securities predicts 2026 will be a year of value reconstruction for the medical device sector, with external pressures leading to improved cash flow for hospitals and procurement decisions [3]. - The medical device industry encompasses a wide range of products and services, with high barriers to entry in the core manufacturing and R&D segments [3]. Group 4: ETF Characteristics - The medical device index ETF (159898) tracks the CSI All-Share Medical Device Index, focusing on sectors such as medical equipment and consumables, with significant holdings in leading companies like Mindray and United Imaging [4]. - The index has a strong representation from the ChiNext and STAR Market, accounting for over 80% of its market cap, highlighting its growth-oriented characteristics [4].

Core Viewpoint - The medical device sector is experiencing significant growth and investment opportunities, driven by recent regulatory approvals and technological advancements in brain-computer interface (BCI) technology [3][4][5]. Group 1: Market Performance - The medical device index ETF (159898) saw a 1.11% increase, with approximately 20 million yuan net inflow during trading [1]. - Key stocks in the medical device sector, such as Yirui Technology and Furu Medical, reported gains of 4.58% and 6.44% respectively, indicating strong market performance [1]. Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) approved two high-value medical devices, enhancing clinical applications and technological development in the industry [3]. - Recent policies from major cities like Shanghai and Beijing aim to support the medical device industry, focusing on regulatory reforms and innovation [5]. Group 3: Technological Advancements - China has made significant progress in invasive brain-computer interface technology, becoming the second country after the U.S. to enter clinical trials [3]. - The global brain-computer interface market is projected to grow from approximately $2.62 billion in 2024 to $12.4 billion by 2034, with a compound annual growth rate of 17.35% [4]. Group 4: Investment Opportunities - Analysts suggest that the medical device sector may replicate the successful path of innovative pharmaceuticals, with a focus on innovation driving industry growth and global competitiveness [5]. - The medical device index ETF (159898) tracks a diverse range of leading companies in the sector, primarily focusing on A-share medical devices [7].

重要声明 本报告依据《公司债券发行与交易管理办法》《关于上海奕瑞光电子科技股 份有限公司向不特定对象发行可转换公司债券之债券受托管理协议》（以下简称 "《受托管理协议》"）《上海奕瑞光电子科技股份有限公司向不特定对象发行 可转换公司债券募集说明书》（以下简称"《募集说明书》"）等相关规定，由 本次债券受托管理人中国国际金融股份有限公司（以下简称"中金公司"）编制。 中金公司对本报告中所包含的从上述文件中引述内容和信息未进行独立验证，也 不就该等引述内容和信息的真实性、准确性和完整性做出任何保证或承担任何责 任。 股票代码：688301 股票简称：奕瑞科技 债券代码：118025 债券简称：奕瑞转债 奕瑞电子科技集团股份有限公司 向不特定对象发行可转换公司债券 第五次临时受托管理事务报告 （2025 年度） 债券受托管理人 二〇二五年十二月 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为中金公司所作的承诺 或声明。在任何情况下，投资者依据本报告所进行的任何作为或不作为，中金公 司不承担任何责任。 1 中国国际金融股份有限公司作为奕瑞电子科 ...